Key facts
- It has raised $70K; the latest was Angel (individual) in Aug 2025.
- Notable investors include Pioneer Group, Polish Agency for Enterprise Development, SMOK Angels.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for intoDNA
- ·The full record, as it builds
Funding rounds
No funding rounds for intoDNA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About intoDNA
Provider of deoxyribonucleic acid research services intended to detect and analyze damaged deoxyribonucleic acid in a human body. The company's services offer enhanced understanding and quality of damaged deoxyribonucleic acid diagnostics and improve any therapies where deoxyribonucleic acid integrity matters, enabling customers in life science research, drug discovery, and development areas to enrich their research with precise deoxyribonucleic acid fragmentation testing.
- Sector
- Healthcare
- HQ
- Krakow, Poland
- Founded
- 2017
- Employees
- 41
- Website
- intodna.com/
- Ownership
- Privately Held (backing)
intoDNA doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in intoDNA shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on intoDNA in its N-PORT filings yet. We sweep new filings monthly.